JPS6154792B2 - - Google Patents

Info

Publication number
JPS6154792B2
JPS6154792B2 JP52144922A JP14492277A JPS6154792B2 JP S6154792 B2 JPS6154792 B2 JP S6154792B2 JP 52144922 A JP52144922 A JP 52144922A JP 14492277 A JP14492277 A JP 14492277A JP S6154792 B2 JPS6154792 B2 JP S6154792B2
Authority
JP
Japan
Prior art keywords
oxazolidinone
group
substituted phenyl
dimethoxyphenyl
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP52144922A
Other languages
English (en)
Japanese (ja)
Other versions
JPS5382777A (en
Inventor
Fuuto Andoreasu
Shumiihien Rarufu
Keeru Uorufuganku
Pasheruke Geruto
Uahateru Herumuuto
Hansu Shunaidaa Heruberuto
Parenshaato Deiitaa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19762655369 external-priority patent/DE2655369A1/de
Priority claimed from DE19772745320 external-priority patent/DE2745320A1/de
Application filed by Schering AG filed Critical Schering AG
Publication of JPS5382777A publication Critical patent/JPS5382777A/ja
Publication of JPS6154792B2 publication Critical patent/JPS6154792B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/16—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP14492277A 1976-12-03 1977-12-02 55*substituted phenyl*oxazolidinone and sulfur homologue thereof process for preparing same and medicine containing same Granted JPS5382777A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19762655369 DE2655369A1 (de) 1976-12-03 1976-12-03 5-(subst. phenyl)-oxazolidinone und deren schwefelanaloga sowie verfahren zu deren herstellung
DE19772745320 DE2745320A1 (de) 1977-10-05 1977-10-05 5-(subst. phenyl)-oxazolidinone und deren schwefelanaloga sowie verfahren zu deren herstellung ii

Publications (2)

Publication Number Publication Date
JPS5382777A JPS5382777A (en) 1978-07-21
JPS6154792B2 true JPS6154792B2 (enFirst) 1986-11-25

Family

ID=25771221

Family Applications (1)

Application Number Title Priority Date Filing Date
JP14492277A Granted JPS5382777A (en) 1976-12-03 1977-12-02 55*substituted phenyl*oxazolidinone and sulfur homologue thereof process for preparing same and medicine containing same

Country Status (19)

Country Link
JP (1) JPS5382777A (enFirst)
AT (1) AT357529B (enFirst)
AU (1) AU519994B2 (enFirst)
CA (1) CA1097657A (enFirst)
CH (1) CH635578A5 (enFirst)
CS (1) CS199694B2 (enFirst)
DD (1) DD133667A5 (enFirst)
DK (1) DK149850C (enFirst)
FR (1) FR2372814A1 (enFirst)
GB (1) GB1588639A (enFirst)
GR (1) GR64964B (enFirst)
HU (1) HU175676B (enFirst)
IE (1) IE46435B1 (enFirst)
IL (1) IL53520A (enFirst)
IT (1) IT1089341B (enFirst)
LU (1) LU78616A1 (enFirst)
NL (1) NL7713153A (enFirst)
SE (1) SE441446B (enFirst)
SU (1) SU888821A3 (enFirst)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01135098U (enFirst) * 1988-03-11 1989-09-14

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2701215C2 (de) * 1977-01-13 1982-10-14 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Thiazolin-2-thionen
US4348393A (en) * 1978-06-09 1982-09-07 Delalande S.A. N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones
DE3438839A1 (de) * 1984-10-19 1986-04-24 Schering AG, 1000 Berlin und 4709 Bergkamen Pharmazeutische praeparate
US5459145A (en) * 1988-01-19 1995-10-17 Pfizer Inc. Calcium independent camp phosphodiesterase inhibitor antidepressant
WO1987006576A1 (en) * 1986-04-29 1987-11-05 Pfizer Inc. Calcium independent camp phosphodiesterase inhibitor antidepressant
WO1991007177A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders
US5461056A (en) * 1992-05-08 1995-10-24 Pfizer Inc. Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders
GB9212673D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
GB9226830D0 (en) * 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
US5622977A (en) * 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
ATE260911T1 (de) * 1993-12-22 2004-03-15 Celltech R&D Ltd Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
GB9326173D0 (en) * 1993-12-22 1994-02-23 Celltech Ltd Chemical compounds and process
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412573D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) * 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
WO1998028281A1 (en) 1996-12-23 1998-07-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01135098U (enFirst) * 1988-03-11 1989-09-14

Also Published As

Publication number Publication date
IE772446L (en) 1978-06-03
FR2372814A1 (fr) 1978-06-30
SE7713635L (sv) 1978-06-04
IL53520A (en) 1981-07-31
GB1588639A (en) 1981-04-29
AU519994B2 (en) 1982-01-07
HU175676B (hu) 1980-09-28
DK149850B (da) 1986-10-13
IE46435B1 (en) 1983-06-15
CA1097657A (en) 1981-03-17
FR2372814B1 (enFirst) 1980-10-10
DD133667A5 (de) 1979-01-17
IT1089341B (it) 1985-06-18
LU78616A1 (enFirst) 1978-04-20
ATA868677A (de) 1979-12-15
AU3117577A (en) 1979-06-07
AT357529B (de) 1980-07-10
IL53520A0 (en) 1978-03-10
CS199694B2 (en) 1980-07-31
SE441446B (sv) 1985-10-07
GR64964B (en) 1980-06-10
JPS5382777A (en) 1978-07-21
DK149850C (da) 1987-04-27
CH635578A5 (en) 1983-04-15
DK536677A (da) 1978-06-04
NL7713153A (nl) 1978-06-06
SU888821A3 (ru) 1981-12-07

Similar Documents

Publication Publication Date Title
JPS6154792B2 (enFirst)
CN1026322C (zh) 苯并哑唑衍生物的制备方法
JP2837139B2 (ja) 耐糖能障害・異常の治療用及び予防用医薬剤
US4186129A (en) 5-(Substituted phenyl)-oxazolidinones and their sulfur analogs
JP2009544620A (ja) 自己免疫疾患及び炎症のためのプロリン尿素ｃｃｒ１アンタゴニスト
CA2950807A1 (en) Dihydropyrimido fused ring derivative as hbv inhibitor
JPH0283384A (ja) 新規化合物、その製法及びそれを含む医薬組成物
JP2000515133A (ja) 血糖降下性および脂質低下性の化合物
JPH0471073B2 (enFirst)
CZ20032452A3 (cs) N-fenylarylsulfonamidová sloučenina, farmaceutická kompozice obsahující tuto sloučeninu jako účinnou složku, syntetický meziprodukt pro tuto sloučeninu a způsob jeho přípravy
JPH0784446B2 (ja) 新規な置換チアゾ−ルおよびオキサゾ−ル化合物
CA2475137C (fr) Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP0841330B1 (fr) Nouveaux dérivés aminométhyl hétérocycliques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
JPH0460597B2 (enFirst)
JP4704914B2 (ja) α−アミノ酸誘導体及びその医薬用途
JPS6058747B2 (ja) アミノ化合物の製法
FR2758329A1 (fr) Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique
JP2000344748A (ja) ３−芳香族置換プロピオン酸またはアクリル酸化合物
KR20040007631A (ko) 티아졸 ｐｐａｒ-리간드 및 이의 다형체의 제조 방법
KR101316653B1 (ko) 헤테로고리 화합물의 제조방법
JP2579116B2 (ja) 新規な４−メチル−１，３−オキサゾール化合物、それらの調製法およびそれらを含む医薬組成物
US6818776B2 (en) Alkali metal salt of thiazolidine-2,4-dione derivative
JP3750141B2 (ja) チアゾリン誘導体
JP3750143B2 (ja) チアゾリン誘導体
JPH04210984A (ja) 環生成されたイミノチアゾールの製法及び中間体